The fifth Liver Forum was held on November 10, 2016 in Boston MA.
Liver Forum 5 had the highest attendance to date, with 230 people attending.
Of those, 165 people attended in-person, and 65 people logged in to the webcast.
Of those, 165 people attended in-person, and 65 people logged in to the webcast.
Materials
Presentations
- Introduction & Updates
Veronica Miller, Forum for Collaborative HIV Research - Regulatory Considerations
Lara Dimick-Santos, U.S. Food and Drug Administration - The Liver Forum Champion of Collaboration
Captain Anissa Davis-Williams, U.S. Food and Drug Administration - FDA’S Biomarker Qualification Program
Shashi Amur, U.S. Food and Drug Administration - FNIH: NASH Biomarker Consortium
Roberto Calle, on behalf of FNIH - Liver Forum - FNIH Collaborations
Arun Sanyal, co-chair FNIH Biomarker Consortium - IMI: Accelerated Drug Portal
Julia Brosnan, on behalf of IMI - Liver Investigation: Testing Marker Utility in Steatohepatitis
Quentin Anstee, Newcastle University Medical School - Disease Definitions Working Group Update
Sophie Megnien, Genfit Corp - Law and Regulations for Trials in Pediatric Patients
Ruby Mehta, U.S. Food and Drug Administration - Regulatory Update from Europe: Paediatric NASH
Elmer Schabel, Bundesinstitut für Arzneimittel und Medizinprodukte - Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease in Children
Jeff Schwimmer, University of California, San Diego School of Medicine - New Working Group Prioritization
Veronica Miller, Forum for Collaborative HIV Research
